Matthieu Siebert1,2, Mohammad Alyami3,4,5,6, Frederic Mercier1,2, Colin Gallice1,2, Laurent Villeneuve1,2, Frédéric Bérard7, Olivier Glehen1,2, Naoual Bakrin1,2, Vahan Kepenekian1,2. 1. Department of Surgical Oncology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France. 2. EMR 3738, Lyon 1 University, Lyon, France. 3. Department of Surgical Oncology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France. swar_ms@hotmail.com. 4. EMR 3738, Lyon 1 University, Lyon, France. swar_ms@hotmail.com. 5. Department of General Surgery and Surgical Oncology, King Faisal Specialist Hospital and research center, Riyadh, Saudi Arabia. swar_ms@hotmail.com. 6. Département de Chirurgie Générale, Digestive et Endocrinienne, CHU Lyon Sud, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France. swar_ms@hotmail.com. 7. Service d'Allergologie et Immunologie Clinique, INSERM U851, Dufourt-5F. CHU Lyon-Sud, Pierre-Bénite, France.
Abstract
BACKGROUND: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) shows encouraging results for patients with unresectable peritoneal metastasis. Several reports demonstrated the safety of the procedure combined with systemic chemotherapy, with a low rate of complication. The aim of this study is to report severe hypersensitivity reactions to platinum compounds (SHRPC) during PIPAC procedures. METHODS: All patients who underwent PIPAC for non-resectable PC in Lyon Sud University hospital were included in a prospective institutional database. All patients who presented a SHRPC after PIPAC were included in our analysis. RESULTS: One hundred and thirty-two patients underwent 383 PIPAC procedures between December 2015 and December 2017. oxaliplatin's and cisplatin-doxorubicin's protocols were used in 71 and 312 PIPAC, respectively. Four patients (3%) developed SHRPC; two patients (2.8%) after oxaliplatin and two patients (0.6%) after cisplatin-doxorubicin protocols. SHRPC occurred during the 6th PIPAC with cisplatin-doxorubicin protocol and during 2nd and 3rd PIPAC of the oxaliplatin protocol. Three events appeared within 15 min and one event occurred 50 min following nebulization. All the SHRPC have been managed successfully without any complication. CONCLUSIONS: This is the first report of SHRPC after PIPAC. The physician must constantly keep this rare but life-threatening complication in mind, especially after repeated PIPAC administration or previous platinum-based systemic chemotherapy.
BACKGROUND: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) shows encouraging results for patients with unresectable peritoneal metastasis. Several reports demonstrated the safety of the procedure combined with systemic chemotherapy, with a low rate of complication. The aim of this study is to report severe hypersensitivity reactions to platinum compounds (SHRPC) during PIPAC procedures. METHODS: All patients who underwent PIPAC for non-resectable PC in Lyon Sud University hospital were included in a prospective institutional database. All patients who presented a SHRPC after PIPAC were included in our analysis. RESULTS: One hundred and thirty-two patients underwent 383 PIPAC procedures between December 2015 and December 2017. oxaliplatin's and cisplatin-doxorubicin's protocols were used in 71 and 312 PIPAC, respectively. Four patients (3%) developed SHRPC; two patients (2.8%) after oxaliplatin and two patients (0.6%) after cisplatin-doxorubicin protocols. SHRPC occurred during the 6th PIPAC with cisplatin-doxorubicin protocol and during 2nd and 3rd PIPAC of the oxaliplatin protocol. Three events appeared within 15 min and one event occurred 50 min following nebulization. All the SHRPC have been managed successfully without any complication. CONCLUSIONS: This is the first report of SHRPC after PIPAC. The physician must constantly keep this rare but life-threatening complication in mind, especially after repeated PIPAC administration or previous platinum-based systemic chemotherapy.
Authors: Koen P Rovers; Emma C E Wassenaar; Robin J Lurvink; Geert-Jan M Creemers; Jacobus W A Burger; Maartje Los; Clément J R Huysentruyt; Gesina van Lijnschoten; Joost Nederend; Max J Lahaye; Maarten J Deenen; Marinus J Wiezer; Simon W Nienhuijs; Djamila Boerma; Ignace H J T de Hingh Journal: Ann Surg Oncol Date: 2021-02-05 Impact factor: 5.344
Authors: Robin J Lurvink; Koen P Rovers; Simon W Nienhuijs; Geert-Jan Creemers; Jacobus W A Burger; Ignace H J de Hingh Journal: J Gastrointest Oncol Date: 2021-04
Authors: Koen P Rovers; Robin J Lurvink; Emma Ce Wassenaar; Thomas Jm Kootstra; Harm J Scholten; Rudaba Tajzai; Maarten J Deenen; Joost Nederend; Max J Lahaye; Clément Jr Huysentruyt; Iris van 't Erve; Remond Ja Fijneman; Alexander Constantinides; Onno Kranenburg; Maartje Los; Anna Mj Thijs; Geert-Jan M Creemers; Jacobus Wa Burger; Marinus J Wiezer; Djamila Boerma; Simon W Nienhuijs; Ignace Hjt de Hingh Journal: BMJ Open Date: 2019-07-27 Impact factor: 2.692